Lifeloc Technologies Reports Revenue Increase and Reduced Net Loss in Q1 2026

Lifeloc Technologies, Inc. reported its financial results for the first quarter of 2026, revealing a modest increase in revenue and a significant reduction in net loss compared to the same period in 2025. The company generated total revenues of $2.29 million, a 1% increase from $2.28 million in the prior year. This growth was primarily driven by a slight uptick in product sales, which reached $2.29 million, up from $2.26 million. Gross profit also improved, rising 9% to $987,074, with a gross profit margin of 43%, up from 40% in the previous year. The decrease in cost of sales, which fell to $1.31 million from $1.37 million, contributed to this enhanced profitability.

In terms of operational performance, Lifeloc's net loss for the quarter was $152,713, a 48% improvement from the net loss of $292,686 reported in the same quarter of 2025. The reduction in losses was attributed to higher gross profit and lower operating expenses, particularly in research and development, which decreased by 12% to $414,445. Sales and marketing expenses also saw a decline of 6%, reflecting the company's ongoing efforts to manage costs amid inflationary pressures affecting raw materials and labor.

Lifeloc continues to focus on strategic developments, particularly the commercialization of its SpinDetect™ technology, which is designed for drug detection. The company has completed the design of the SpinDetect™ microfluidic disk and is initiating beta testing, with a commercial launch anticipated in 2026. This new product line is expected to expand Lifeloc's market presence beyond alcohol detection into drug testing, potentially increasing its market share and customer base.

As of March 31, 2026, Lifeloc's total assets stood at $6.74 million, with current assets of $4.37 million, including cash and cash equivalents of $569,330. The company reported current liabilities of $1.06 million, resulting in net liquid assets of $355,570. The company’s employee headcount remains stable, and it continues to pursue acquisitions that align with its mission to enhance its product offerings and market reach.

Looking ahead, Lifeloc anticipates that its installed base of breathalyzers will grow as awareness of the risks associated with alcohol consumption increases. The company aims to leverage its expanding distributor network and marketing efforts to drive sales growth. However, it acknowledges the potential for continued operating losses as it invests in the development of SpinDetect™. The company remains committed to managing costs while advancing its product development initiatives, with the expectation that cash resources will be sufficient to fund operations for the next twelve months.